Abstract 18633: Outcome Among VT or VF Patients in the Lucas in Cardiac Arrest Randomized Controlled Trial - A Subgroup Analysis
Introduction: The aim of this analysis was to evaluate outcome among patients with VT/VF in the LINC trial and its association to delayed defibrillation and the amount of adrenaline used.
Methods: The LINC database was searched for patients with an initial rhythm of VT or VF. The data were analysed with regards to return of spontaneous circulation (ROSC) anytime, 4-hour survival, survival with good neurological outcome to intensive care unit (ICU) discharge, to hospital discharge, at 1 and 6 months. ROSC and survival was also evaluated in relation to CPR time. Number of defibrillation and injection of adrenalin given were analysed in relation to outcome.
Results: There were a significant difference between the two groups regarding time from start of manual chest compressions to the first defibrillation (Mechanical CPR: 4 (3-5) min vs Manual CPR 3 (2-4) min, P <0.001), from ambulance arrival to start of transport (Mechanical CPR: 26 (20-34) min vs Manual CPR 24 (18-32) min, P <0.001), from ambulance arrival to arrival to hospital (Mechanical CPR: 35 (28-45) min vs Manual CPR 33 (25-43) min, P 0.007). There were no difference in 4 hour survival (Mechanical CPR: 46.3% vs. Manual CPR: 49.3%, P = 0.941) or 6 months survival with good neurological outcome (Mechanical CPR: 25.1% vs. Manual CPR: 23.0%) between the two treatment groups. Time from start of manual chest compression to first detected ROSC was longer in the Mechanical CPR group, this differences however disappeared after 50 min. No differences in the number of defibrillations or adrenalin injections given to patients with or without ROSC could be noted.
Conclusions: In the LINC-trial the overall survival rate among VT/VF patients are similar comparing the Manual and Mechanical CPR group despite the time differences regarding defibrillations noted between the two treatments algorithms. Adrenalin dosing are similar in both groups and has not influenced outcome when comparing the groups.
Author Disclosures: B. Madsen Hardig: Employment; Significant; Is an employee of the company Physio-Control/Jolife AB producing the LUCAS device. O. Östlund: None. E. Lindgren: None. J. Herlitz: None. R. Karlsten: None. S. Rubertsson: Consultant/Advisory Board; Modest; Jolife AB/PhysioControl. Research Grant; Significant; Laerdal Fondation for Acute medicine, Swedish HeartLung Fondation, Institutional Grants Uppsala University. Other; Significant; PI for the DISCO trial.
- © 2016 by American Heart Association, Inc.